Common Genetic Risk Seen for Primary Ovarian Insufficiency, Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 31, 2024 -- There seems to be a common genetic risk for primary ovarian insufficiency (POI) and reproductive cancer risk, according to a study published online July 12 in the Journal of Clinical Endocrinology & Metabolism.
Kristina Allen-Brady, Ph.D., M.P.H., from the Huntsman Cancer Institute at the University of Utah in Salt Lake City, and colleagues conducted a case-control population-based study using records from 1995 to 2022 to examine whether a subset of women with POI and their family members have an increased risk for cancer. The analyses included 613 women with POI and their relatives from two major Utah academic health care systems.
The researchers observed a significant increase in breast cancer among women with POI (odds ratio, 2.20) and a nominally significant increase in ovarian cancer. Probands with POI were aged 36.5 ± 4.3 years when diagnosed with POI and were aged 59.5 ± 12.7 years when diagnosed with cancer. Causal and candidate gene variants were identified for cancer and POI. An increased risk for breast and colon cancer (odds ratios, 1.28 and 1.50, respectively) was seen among second-degree relatives of these women. The risk for prostate cancer was increased in first-, second-, and third-degree relatives (odds ratios, 1.64, 1.54, and 1.33, respectively).
"Our data suggest that a subset of women with POI need counseling regarding future cancer risk," the authors write. "Recommendations will likely depend on underlying family history and genetic risk."
Several authors disclosed financial ties to Fabric Genomics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
American College of Obstetricians and Gynecologists, May 16-18
The annual meeting of the American College of Obstetricians and Gynecologists (ACOG) was held from May 16 to 18 in Minneapolis and was attended by more than 4,000...
Bilateral Salpingo-Oophorectomy Beneficial in BRCA1/2 Carriers With Personal History of Breast Cancer
TUESDAY, May 13, 2025 -- For carriers of pathogenic variants in BRCA1 and BRCA2 with a personal history of breast cancer, bilateral salpingo-oophorectomy (BSO) is beneficial...
Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer
MONDAY, May 12, 2025 -- The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.